These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 29703539)

  • 21. Identification of a novel ALK inhibitor-sensitive PRKCE-ALK gene fusion in lung adenocarcinoma.
    Wang L; Li L; Zhou X; Zhang D
    Lung Cancer; 2024 May; 191():107797. PubMed ID: 38669726
    [No Abstract]   [Full Text] [Related]  

  • 22. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
    Shiihara J; Ohyanagi F; Amari H; Toda M; Tahara H; Yuzawa M; Maeda Y; Nomura M; Mizushina Y; Nagai Y; Ohta H; Yamaguchi Y
    Thorac Cancer; 2021 Sep; 12(17):2420-2423. PubMed ID: 34324792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma.
    Liu Z; Wu Q; Li W; Li P; Huang L; Wang T; Zhou Q
    Lung Cancer; 2023 Dec; 186():107386. PubMed ID: 37922771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
    Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S
    Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.
    He Z; Wu X; Ma S; Zhang C; Zhang Z; Wang S; Yu S; Wang Q
    Clin Lung Cancer; 2019 Sep; 20(5):e548-e551. PubMed ID: 31281052
    [No Abstract]   [Full Text] [Related]  

  • 26. A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma.
    Wang T; Du G; Niu M; Liu R
    BMC Pulm Med; 2023 Feb; 23(1):60. PubMed ID: 36755262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
    Koyama K; Katsurada N; Jimbo N; Tachihara M; Tamura D; Nakata K; Nagano T; Yamamoto M; Kamiryo H; Kobayashi K; Itoh T; Nishimura Y
    Pathol Int; 2019 May; 69(5):294-299. PubMed ID: 30900377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SMPD3-ALK: A novel ALK fusion gene in lung adenocarcinoma.
    Liang Y; Wang Y; Wang W; Zhao J; Xu M; Zheng M
    Clin Genet; 2021 Mar; 99(3):488-489. PubMed ID: 33556194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report.
    Tang Q; Li T; Ren F; Li X; Cao W; Yu H; Mao F; Cao C; Zu L; Xu S
    J Natl Compr Canc Netw; 2024 Feb; 22(2):. PubMed ID: 38364363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
    Wang Z; Wu R; Li C; Cheng K; Di Y; Lv T; Liu H; Song Y
    Anticancer Drugs; 2023 Nov; 34(10):1069-1075. PubMed ID: 36688904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation.
    Baglivo S; Ricciuti B; Ludovini V; Metro G; Siggillino A; De Giglio A; Chiari R
    J Thorac Oncol; 2018 Aug; 13(8):e145-e147. PubMed ID: 30049377
    [No Abstract]   [Full Text] [Related]  

  • 32. Identification of a novel LRRC4C-ALK fusion in lung adenocarcinoma and outcome of the response to anaplastic lymphoma kinase inhibitors.
    Wang H; Li Z; Qi X; Wang W; Lin Y
    J Gene Med; 2021 Mar; 23(3):e3316. PubMed ID: 33559138
    [No Abstract]   [Full Text] [Related]  

  • 33. Chr2 30297612-ALK, A Novel Intergenic Fusion With Exon18 of ALK, Responds to Crizotinib.
    Chen X; Zhao G; Zhong P; Zhang M; Chen R; Zhang D
    Clin Lung Cancer; 2020 Nov; 21(6):e564-e566. PubMed ID: 32576444
    [No Abstract]   [Full Text] [Related]  

  • 34. A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib.
    Lim CA; Banyi N; Tucker T; Ionescu DN; Melosky B
    Curr Oncol; 2022 Feb; 29(2):848-852. PubMed ID: 35200571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of Alectinib in a Patient With Advanced NSCLC Undergoing Hemodialysis.
    Suzuki S; Haratani K; Takahama T; Watanabe S; Takegawa N; Hayashi H; Takeda M; Yonesaka K; Nakagawa K
    J Thorac Oncol; 2019 Mar; 14(3):e50-e52. PubMed ID: 30782383
    [No Abstract]   [Full Text] [Related]  

  • 36. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
    Hayashi N; Fujita A; Saikai T; Takabatake H; Sotoshiro M; Sekine K; Kawana A
    Intern Med; 2018 Mar; 57(5):713-716. PubMed ID: 29151522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Molecular diagnostics of ALK-positive lung cancer].
    Tímár J; Lotz G; Rásó E; Moldvay J
    Magy Onkol; 2017 Sep; 61(3):301-311. PubMed ID: 28931104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
    Shirasawa M; Kubotaa M; Harada S; Niwa H; Kusuhara S; Kasajima M; Hiyoshi Y; Ishihara M; Igawa S; Masuda N
    Lung Cancer; 2016 Sep; 99():66-8. PubMed ID: 27565916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC.
    Fang W; Gan J; Hong S; Lu F; Zhang L
    J Thorac Oncol; 2019 Jul; 14(7):e148-e151. PubMed ID: 31235041
    [No Abstract]   [Full Text] [Related]  

  • 40. Alectinib-responsive infantile anaplastic ganglioglioma with a novel VCL-ALK gene fusion.
    Yamamoto S; Koga Y; Ono H; Goto H; Hata N; Yamamoto H; Suzuki SO; Sakai Y; Iwaki T; Ohga S
    Pediatr Blood Cancer; 2021 Sep; 68(9):e29122. PubMed ID: 34019333
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.